You can buy or sell Vericel and other stocks, options, ETFs, and crypto commission-free!
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio includes MACI and Epicel. Read More The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns comprising a total body surface area of greater than or equal to 30%. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Seeking AlphaMay 21
MediWound Ltd.'s CEO Sharon Malka on Q1 2019 Results - Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD) Q1 2019 Results Earnings Conference Call May 21, 2019 8:30 AM ET Company Participants Jeremy Feffer - Managing Director Steve Wills - Chairman Sharon Malka - Chief Executive Officer Conference Call Participants Raj Denhoy - Jefferies Josh Jennings - Cowen Jay Olson - Oppenheimer Operator Good day, ladies and gentlemen. And welcome to the MediWound First Quarter 2019 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a ques...
Yahoo FinanceMay 15
Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019
CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 2019 UBS Global Healthcare Conference in New York City on Wednesday, May 22, 2019 at 10:30am Eastern Time. A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: htt...
Yahoo FinanceMay 9
Were Hedge Funds Right About Dumping Vericel Corp (VCEL) ?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates.
Expected Aug 5, Pre-Market